SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

M. Majem ^[1] ; O. Juan ^[9] ; A. Insa ^[2] ; N. Reguart ^[3] ; J. M. Trigo ^[4] ; E. Carcereny ^[5] ; R. García-Campelo ^[6] ; Y. García ^[10] ; M. Guirado ^[7] ; M. Provencio ^[8]
1. [1] Hospital de la Santa Creu i Sant Pau
  
  Hospital de la Santa Creu i Sant Pau
  
  Barcelona, España
2. [2] Hospital Clinico Universitario de Valencia
  
  Hospital Clinico Universitario de Valencia
  
  Valencia, España
3. [3] Hospital Clinic Barcelona
  
  Hospital Clinic Barcelona
  
  Barcelona, España
4. [4] Hospital Universitario Virgen de la Victoria
  
  Hospital Universitario Virgen de la Victoria
  
  Málaga, España
5. [5] Institute Catalá Oncología
  
  Institute Catalá Oncología
  
  Barcelona, España
6. [6] Complexo Hospitalario Universitario da Coruña
  
  Complexo Hospitalario Universitario da Coruña
  
  A Coruña, España
7. [7] Hospital General Universitario de Elche
  
  Hospital General Universitario de Elche
  
  Elche, España
8. [8] Hospital Universitario Puerta de Hierro
  
  Hospital Universitario Puerta de Hierro
  
  Madrid, España
9. [9] Hospital Universitari i Politècnic La Fe
10. [10] Institut d’Investigació i Innovació Parc Taulí I3PT
Mostrar afiliaciones +
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 1 (January 2019), 2019, págs. 3-17
Idioma: inglés
Texto completo no disponible (Saber más ...)

Resumen
- Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment attains greater value.